Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Dual-drug therapy targets one colon cancer gene

17.08.2005


Johns Hopkins Kimmel Cancer Center scientists have found that interferon, used for 30 years to treat blood cancers, multiple sclerosis and hepatitis, selectively kills colon cancer cells when combined with another standard chemotherapy agent. New studies in cell lines suggest that the combination tactic, which targets a common gene pathway in colon cancer cells, could be more potent than either drug alone, and has fewer side effects.



"Instead of killing a tree by chopping it down, this approach focuses on cutting off the diseased branch, leaving the rest of the tree relatively unscathed," says Betsy Barnes, Ph.D., assistant professor of oncology and lead researcher.

By itself, interferon’s cell-killing activity is non-specific in targeting a variety of cells and cell-based gene activity, causing serious side effects such as heart failure and low blood counts, in addition to killing cancer cells. But in an August 15 issue of Cancer Research, the Kimmel Cancer Center scientists found one factor in interferon’s makeup that could have cancer-killing qualities, but with fewer side effects since it activates fewer genes.


Specifically, the team found that IRF5 (Interferon Regulatory Factor-5), which works as a tumor suppressor to halt cancer cell growth, is turned off by many cancers, but low levels of the suppressor protein are found in most colon cancers. That led Hopkins’ Barnes and her team to pursue its potential.

The first thing they found is that although interferon boosts IRF5 protein levels in colon cancer cells, it does not raise it enough to kill the cells. To boost IRF5 levels, the investigators combined interferon with a chemotherapy drug called irinotecan (CPT-11), a drug that damages DNA in rapidly dividing cells, rendering them unable to divide.

"We believe that interferon and irinotecan both work to increase IRF5 protein levels, but irinotecan activates the protein in the final step to initiate cancer cell death," says Barnes.

To demonstrate their theory that IRF5 is a key ingredient in the dual-drug therapy, the scientists tested various combinations of the drugs in colon cancer cell lines, with or without IRF5. Irinotecan alone causes 65 percent cell death in lines with IRF5 proteins present. Knock out IRF5 proteins and cell deaths drop to 37 percent. When the investigators combined irinotecan and interferon, more than 80 percent of colon cancer cells with IRF5 proteins died. Only 28 percent of cells died in those lines with IRF5 proteins knocked out.

"Not only does the combination of these drugs involve fewer gene activations, it may allow use of smaller amounts of both drugs and limit side effects," says Barnes. She also believes that cancer cells may find it more difficult to build resistance to two different drugs, a common problem when using single agents.

Cancers lacking tumor suppressor genes and the proteins they make are often difficult to treat because cells are unable to put the brake on abnormal growth. Her study indicates that IRF5 applies the brakes even in the absence of other tumor suppressor genes.

It is not clear whether the combination therapy would work in other cancers, since IRF5 is absent in a number of blood cancers. But since colon cancer is the third deadliest cancer in the United States, Barnes and her team will conduct further tests in genetically modified mice and potentially create a new strategy to treat the disease.

Colon cancer strikes more than 100,000 people in the United States annually and kills more than 56,000.

Funding for this research was provided by the American Cancer Society and a Flight Attendant Medical Research Institute Young Clinical Scientist Award.

Barnes’ research team on this study included Guodong Hu and Margo E. Mancl from Johns Hopkins.

Vanessa Wasta | EurekAlert!
Further information:
http://www.jhmi.edu
http://www.hopkinskimmelcancercenter.org
http://www.hopkinscoloncancercenter.org

More articles from Life Sciences:

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

nachricht Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Periodic ventilation keeps more pollen out than tilted-open windows

29.03.2017 | Health and Medicine

Researchers discover dust plays prominent role in nutrients of mountain forest ecoystems

29.03.2017 | Earth Sciences

OLED production facility from a single source

29.03.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>